— Know what they know.
Not Investment Advice

CNCE NASDAQ

Concert Pharmaceuticals, Inc.
1W: -0.1% 1M: -0.2% 3M: +73.7% 1Y: +171.8% 3Y: -12.0% 5Y: -60.2%
$8.37
Last traded 2023-03-03 — delisted
NASDAQ · Healthcare · Biotechnology

Cash Flow Trends

Operating Cash Flow
-$55M +20.1% ▲
Capital Expenditures
$255K -21.4% ▼
5Y CAGR: -19.8%
Free Cash Flow
-$55M +20.0% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$64M +166.7% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2017FY2018FY2019FY2020FY2021
— Operating Activities —
Net Income$96M-$56M-$78M-$75M-$80M
Depreciation & Amort.$1M$1M$2M$2M$1M
Stock-Based Comp.$8M$12M$10M$11M$13M
Change in Working Capital-$4M$4M$16M-$11M$8M
Other Non-Cash Items$1M-$9M$226K$284K$383K
Operating Cash Flow$103M-$48M-$49M-$69M-$55M
— Investing Activities —
Capital Expenditures-$947K-$3M-$685K-$210K-$255K
Acquisitions (Net)$0$0-$83M$0$0
Investment Purchases-$206M-$99M-$98M-$157M$0
Investment Sales$86M$140M$181M$157M$53M
Other Investing$0$0$83M$0$0
Investing Cash Flow-$121M$38M$83M$344K$52M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0-$1M-$740K$0$0
Dividends Paid$0$0$0$0$0
Other Financing$5M-$169K$1M$93M$67M
Financing Cash Flow$5M-$169K$1M$93M$67M
Net Change in Cash-$13M-$10M$35M$24M$64M
Cash End of Period$28M$19M$54M$78M$143M
Free Cash Flow$102M-$51M-$49M-$69M-$55M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms